Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
FL.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22683US
B.1.578NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.544NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
B.1.448NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.425NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.354NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.503NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-21599.5US
B.1.36.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.623NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.214.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.588NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.210NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GM.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.44NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FU.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FV.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GJ.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.22.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FE.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBL.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.56NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GR.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.568NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.1.13 (Gamma)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.372NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.634NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.37.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.630NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.360NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.23.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JE.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.83NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.32NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HN.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HK.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.24.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GK.1.8.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LA.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
LN.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.25.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.16.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used